OCS recalls mint CBD spray for being an unlicensed prescription drug

| Staff

The Ontario Cannabis Store (OCS) has issued a product recall for a Mint CBD spray it says is classified as an unlicensed prescription drug.

The recall, issued on May 25, is for Feather brand’s Dream Mint CBD Rapid Spray from Motif Labs Ltd. The product is no longer listed by the OCS.ca

The OCS shared a similar product recall in April for a CBD product they said was an unapproved prescription drug. The CBD soft gels were previously listed on the OCS website as each containing 20 mg of CBD, zero THC, as well as 10 mg of melatonin, and chamomile oil. 

No other details on why the Dream Mint CBD spray was recalled were provided. The product package date on the recalled units was February 7, 2023 to March 19, 2023.

The Lot number is S80FTHDM22043, product number is 108039 and the SKU is 108039_8.23ml___. Some retailers list the product as also containing melatonin, as does an archived version of Feather’s website, saying the product is “Stabilized with Melatonin”.

Health Canada regulates melatonin under the Natural Health Products Regulations. It’s commonly advertised as an effective sleep aid; however, some medical experts warn that it can cause side effects such as dizziness, nausea, headaches, and muscle aches if used in high doses.

Health Canada recently issued a product recall for a CBD product on April 4 that contained 20mg of CBD and 3mg of Melatonin, calling it an “unauthorized product.” The notice said it was a product sold without market authorization (DIN) in Canada. A DIN is a Drug Identification Number.